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transplantation is clearly attributable to the dysfunction of defen-
sive mechanisms of the host, both as a result of cirrhosis, as well
as the use of immunosuppressive agents.
The present document represents the recommendations of an
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Due to a decreased response to vaccinations in cirrhosis as well as
within the ﬁrst six months after transplantation, the best timing
for immunization is likely before transplant and early in the
course of disease. Before transplantation, a vaccination panel
including inactivated as well as live attenuated vaccines is rec-
ommended, while oral polio vaccine, Calmette-Guerin’s bacillus,
and Smallpox are contraindicated, whereas after transplantation,
live attenuated vaccines are contraindicated. Before transplant,
screening protocols should be divided into different levels
according to the likelihood of infection, in order to reduce costs
for the National Health Service. Recommended preoperative
and postoperative prophylaxis varies according to the pathologic
agent to which it is directed (bacterial vs. viral vs. fungal). Timing
after transplantation greatly determines the most likely agent
involved in post-transplant infections, and speciﬁc high-risk cat-
egories of patients have been identiﬁed that warrant closer sur-
veillance. Clearly, speciﬁcally targeted treatment protocols are
needed upon diagnosis of infections in both the pre- as well as
the post-transplant scenarios, not without considering local
microbiology and resistance patterns.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Risk of pretransplantation infections
The identiﬁcation and selection of a candidate for liver transplan-
tation is a complex process that requires a team approach. Both
indications and contraindications can change over time, reﬂect-
ing advances in understanding of and ability to treat certain14 vol. 60 j 1075–1089
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disease processes [1] including infections. A practical clinical
approach to the management of patients with cirrhosis during
transplant selection [2] includes the evaluation of the infectious
risk, aiming to prevent or reduce both the risk of infection-related
drop out from the waiting list and the negative impact on the
outcome after LT.
Patients with cirrhosis often develop sepsis as a result of the
dysfunction of the defensive mechanisms against bacterial, viral
or fungal infections [3]. The overall mortality of infected
patients is reported to be as high as 38% (odds ratio for death
of infected vs. non-infected patients of 3.75) [4]. Spontaneous
bacterial peritonitis (SBP) represents one of the most common
infectious complications reported in patients with cirrhosis
while waiting for LT.
Liver transplantation is a major, lengthy and complex surgical
procedure performed on severely ill patients. Therefore identiﬁca-
tion, control, decolonization, and eradication of either bacterial,
viral, fungal, or parasitic infections is paramount. A microbial
burden that may be kept under control by the host’s immune
system before transplant may acquire notable relevance after
the combination of major surgery and immunosuppression.
Risk of post-transplantation infections
Bacterial infections, especially those involving gram-negative
bacteria, represent a major complication in liver transplant recip-
ients, the frequency ranging between 20% and 80% of cases, and
they contribute to longer hospital stays and increased hospital
costs [5]. Three-fourths of bacterial infectious episodes occur in
the ﬁrst month after transplantation [6]. Most of these infections
are endogenous and arise from aerobic gram-negative bacteria
(GNB) and yeasts that have colonized the oropharynx, stomach
and bowel [7].
The role of selective digestive tract decontamination (SDD)
with antibiotics in the prevention of bacterial infections in liver
transplant recipients is still a matter of debate [8]. A recent study
from Spain did not conﬁrm that ﬂuoroquinolones administered
from the time of transplantation have any protective effect
against the development of early bacterial infections after liver
transplantation [6].
Liver transplant recipients may be at risk for developing
mycobacterial infections due to latent tuberculosis (TB). How-
ever, once the diagnosis is made and the speciﬁc treatment is
adopted, patient survival is similar to that of liver transplant
recipients without latent TB [9].
Invasive fungal infections (IFI) and Cytomegalovirus (CMV)
infection are important causes of morbidity and mortality in liver
transplant recipients. A signiﬁcant reduction in both fungal and
CMV infections was demonstrated by adopting prophylactic
regimens [10–12].
Aims
The goal of this document is to provide clinical guidelines for the
appropriate management of infections in the setting of liver
transplantation.
Methods
The promoter of these ‘‘Consensus Guidelines’’ was the Italian
association for the Study of the Liver (AISF), which identiﬁed a1076 Journal of Hepatology 2014scientiﬁc board of Experts in charge of the document preparation.
The Consensus was endorsed by the Italian society for Infectious
and Tropical Diseases (SIMIT). The scientiﬁc board deﬁned the
methodology utilized as well as the goals, and acted as developer
and reviewer. The methodology chosen involved the following
steps:
(a) The promoters and the scientiﬁc board selected the main
topics of interest: (1) Epidemiology of infections in the
transplant setting, (2) Pre-LT infectious work up, (3) Man-
agement of infections in the post-LT, (4) Treatment of
infections in liver transplantation.
(b) For each topic, a working party was identiﬁed by both the
promoters and the scientiﬁc board, and was composed of
a group of at least four experts guided by a chairman. The
chairman, together with the promoters and the scientiﬁc
board, selected the relevant clinical questions regarding
both clinical practice and controversial areas. The questions
were circulated within the working groups to reﬁne the
topics and to avoid duplications. The members of the work-
ing parties were identiﬁed on the basis of competence, role,
expertise and publications/research in the ﬁeld of infec-
tions, end stage liver disease and liver transplantation.
(c) The working groups independently carried out a sys-
tematic literature search and review, using Medline/
PubMed to support deﬁnitions and statements. Each
recommendation was graded according to the Centre
for Disease Control’s (CDC grading system, Supplemen-
tary Table 1)
(d) The working groups elaborated the proposed statements,
graded according to the selected grading system. They pre-
pared the statements together with the presentation of the
literature review for each topic during video-conferences,
group meetings, and correspondence before the Consensus
Conference
(e) The jury members were by no means involved in the selec-
tion, preparation, and discussion of the topics and state-
ments prior to the Consensus Conference.
(f) All the promoters, members of the scientiﬁc board, work-
ing groups, and jury invited to participate to the Consensus
Conference were asked to declare any potential conﬂict of
interests.
A Consensus Meeting was held in Bergamo in 2012. The con-
sensus group consisted of a total of 124 participants (including
promoters, scientiﬁc board, working groups, jury). The jury was
selected among infectious disease specialists, hepatologists,
microbiologists, intensive care physicians, surgeons, epidemiolo-
gists, patient representatives and ethicists. During the ﬁrst ses-
sions, the chairman of each group presented the selected topics
and the proposed statements for each question. A general discus-
sion was held in order to reﬁne the statements and identify the
possible adjustments. At the end of the general session, each
group met independently to re-elaborate the ﬁnal statements to
be presented in the ﬁnal voting session according to the sugges-
tions received. The ﬁnal general session consisted in the presen-
tation of every single statement by the chairman of each working
group, followed by an electronic vote from the jury. The agree-
ment scale consisted of 2 levels of agreement (Agree, Disagree).
The results of jury voting are available online as Supplementary
data.vol. 60 j 1075–1089
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Vaccination and liver transplantation
Pretransplantation
Despite emerging evidence that vaccinations are safe and effec-
tive among immunosuppressed patients, most vaccines are still
underutilized in these patients. The efﬁcacy, safety, and proto-
cols of several vaccines in this patient population are poorly
understood. Timing of vaccination appears to be critical
because response to vaccinations is decreased in patients with
end-stage organ disease and within the ﬁrst 6 months after
transplantation. In addition, liver transplant candidates might
often wait for an unpredictable length of time before a suitable
donor is available, and during this interval, all recommended
vaccinations as well as boosts should be given. Although vacci-
nation responses in some patients awaiting transplantation are
suboptimal, antibody responses are usually even more attenu-
ated when vaccines are administered after transplantation
[13–15]. For these reasons, primary immunizations should be
given before transplantation, and as early as possible during
the course of disease. The vaccination strategy should include
vaccination of household contacts and health care workers at
transplant centres, unless contraindicated. In the transplant
population, however, no conclusive data are available on the
use of immune-adjuvants and on the screening for protective
titres. Nevertheless, most vaccines appear to be safe in solid-
organ transplantation recipients, but live vaccines should be
avoided until further studies are available. The risk of rejection
following vaccinations appears to date minimal.
The following are the indicated vaccinations for paediatric
transplant candidates [16]: Inactivated: Inﬂuenza, Hepatitis A
and B, Pertussis, Diphtheria, Tetanus, Polio (inactivated),
Haemophilus inﬂuenzae, Streptococcus pneumoniae (conjugated or
polysaccharide vaccine), and Neisseria meningitidis. Live attenu-
ated: Varicella, Measles, Mumps, and Rubella. Rabies vaccine is
not routinely administered, and is recommended for exposures,
or potential exposures due to vocation or avocation. Smallpox
and anthrax vaccinations are not routinely recommended in the
pretransplant setting.
In adult liver transplantation candidates, the following vacci-
nations are indicated [16]: Inactivated: Inﬂuenza, Hepatitis A and
B, Tetanus, Polio (inactivated), Streptococcus pneumoniae (conju-
gated or polysaccharide vaccine) and Varicella (live attenuated).
Other vaccinations are indicated in special circumstances:
Neisseria meningitidis is recommended in members of the mili-
tary, travellers to high risk areas, in cases of properdin deﬁciency,
terminal complement component deﬁciency, and in patients with
functional or anatomic asplenia.
Speciﬁc contraindications exist for other vaccines,
including the oral polio vaccine, Calmette-Guerin’s bacillus, and
Smallpox.
Post-transplantation
Current data seem to support the assumption that solid-organ
recipients will beneﬁt from consistent immunization practices;
however, further studies are recommended to improve estab-
lished protocols in this patient population [17].
In general, the following vaccinations are recommended for
paediatric transplant recipients [16]: Inactivated: Inﬂuenza,Journal of Hepatology 2014Hepatitis A, Pertussis, Diphtheria, Tetanus, Polio (inactivated),
Haemophilus inﬂuenzae, Streptococcus pneumoniae (conjugated or
polysaccharide vaccine), and Neisseria meningitidis. On the con-
trary, live attenuated vaccines including Varicella, Measles,
Mumps, Rubella, BCG, and smallpox are contraindicated. The
Hepatitis B vaccine is poorly immunogenic after transplantation.
Serial hepatitis B surface antibody titres should be assessed both
before and after transplantation to evaluate the adequacy of the
elicited immune response. The following vaccines are
recommended for adult transplant recipients [16]: Inactivated:
Inﬂuenza, Hepatitis A, Tetanus, Polio Polio (inactivated), Strepto-
coccus pneumonia. Regarding Hepatitis B virus vaccination after
transplantation, it is poorly immunogenic, and accelerated
schedules may be yet less immunogenic. Rabies vaccine is recom-
mended only for exposures, or potential exposures due to voca-
tion or avocation. On the contrary, live attenuated vaccines are
contraindicated: Varicella, BCG, and Smallpox.Statements
Pretransplantation
Question 1.a
Is it advisable to deﬁne different levels of infectious screening for
liver transplant candidates warranting accuracy and reducing
costs for the National Health Service and efforts for the patients?
Statement 1.a
The infectious screening in liver transplant recipients should be
graduated in different levels, warranting both accuracy and
reduction of costs for the National Health Service (III C):
Level 1? to be performed in all patients candidate to liver
transplantation
Level 2? to be performed only in patients eligible to liver
transplantation at the time of listing
Level 3? to be performed in patients with risk factors or from
geographic area endemic for speciﬁc infections
Question 1.b
Which are the levels of screening for infections in liver transplan-
tation candidates?
Statement 1.b1
 First level screening to be performed to all patients candidate
to liver transplantation (if not available in the previous
3 months) (III C):vol. 6– Human immunodeﬁciency virus (HIV) 1 and 2 Abs
– Hepatitis B virus (HBV) serology: HBsAg, HBcAb, HBsAb
 if HBsAg pos? HBeAg/HBe Ab; HBV-DNA, Hepatitis D
virus (HDV) IgG
 if HBcAb pos? HBV-DNA– Hepatitis C virus (HCV) Ab? if positive, HCV-RNA and
HCV genotype
– Hepatitis A virus (HAV) Ab IgG
– Chest X-ray0 j 1075–1089 1077
Statement 1.b2
 Second level screening to be performed to all patients eligible to
liver transplantation, at listing (III C).
– Mycobacterium tuberculosis: history + Tuberculin skin test
(PPD-Mantoux) + Interferon-Gamma Release Assays
(IGRAs) (II A)
– Cytomegalovirus: CMV IgG; CMV-DNA is not recom-
mended before liver transplantation
– Epstein Barr virus (EBV): EBV VCA IgG and EBNA Ab
– Human herpes virus 8 (HHV-8) IgG (anti-lytic and anti-
latent antibodies)
– Varicella zoster virus (VZV), Herpes simplex virus 1 (HSV-
1), Herpes simplex virus 2 (HSV-2) IgG
– Urine culture
– Parasitological exam and stool culture (Strongyloides
stercoralis serology, Toxoplasma gondii IgG, Treponema pal-
lidum serology - Immune-enzymatic assay with VDRL or
RPR if positive -), Staphylococcus aureus nasal/axillary
swab
– Dental X-ray or dental scan
Frontiers in Liver TransplantationStatement 1.b3
Third level screening to be performed to a subset of patients
according to the clinical history, comorbidities and to endemic
diseases and local epidemiology following ID Consult (III C).
– Vancomycin-resistant Enterococcus (VRE) and multidrug-
resistant (MDR) Gram (-) rectal swab
– Serology for: Histoplasma, Coccidiomycosis, Trypanosome,
Schistosoma, Leishmania
– Malaria blood test
– Human T cell lymphotropic viruses (HTLV) 1–2 IgGQuestion 1.c
Prophylaxis of tuberculosis infection: Who?
Statement 1.c
Prophylaxis of TB should be considered in all patients candidate
to liver transplant with:
– PPD-Mantoux P5 mm after 48–72 h and IGRAs positive (II A)
– Recent close exposure to person with active TB (II A)
– PPD-Mantoux <5 mm and IGRAs positive (II B)
– PPD-Mantoux P10 mm and IGRAs negative (III B)
– In case of indeterminate IGRAs? ID Consult is recommended
(III B)
Comment: A systematic review of 7 studies estimated that,
compared with the general population, liver transplant recipients
have a 18-fold increase in the prevalence of activeMycobacterium
tuberculosis infection and a 4-fold increase in the case-fatality
rate [18] (Supplementary Table 2).
IGRA (Quantiferon TB Gold test or T-spot TB) must be per-
formed, together with PPD, due to the high rate of false negative
PPD test in immunodeﬁcient patients [19,20].
Question 1.d
Prophylaxis of tuberculosis infection: Which is the proper
schedule?1078 Journal of Hepatology 2014Statement 1.d
– Recommended treatment scheduled is: Isoniazid 5 mg/kg/d,
(max 300 mg/d) + Vit. B6 for 6–9 months (II A)
– In case of chest X-ray evidence of ﬁbrotic lesions and PPD
P5 mm, IGRAs positive and no previous TB therapy, treat-
ment should be prolonged up to 9 months (II B)
Comment: In case of isoniazid-resistance or intolerance,
rifampicin (10 mg/kg/d, max 600 mg/d, for 4 months) or
ethambutol + levoﬂoxacin according to ID consult can be indi-
cated. Except for isoniazid-resistance, no different therapeutic
regimens can be recommended, as no better efﬁcacy has been
documented and due to the major risk of both toxicity and
drug-interactions.
Question 1.e
Prophylaxis of tuberculosis infection: When?
Statement 1.e
– Treatment for TB infection should be started before liver
transplant whenever feasible and tolerated (II A)
– The initiation of post- transplant preventive treatment for TB
infection should begin as soon as a patient’s liver function has
stabilized to prevent the development of reactivated diseases
(II A)
Comment: A low efﬁcacy of vaccination has been documented
and TB vaccination is not recommended in liver transplant candi-
dates. Although it would be optimal to treat TB infection prior to
liver transplantation, it is challenging due to potential isoniazid
hepatotoxicity.
Mortality rate is higher in liver transplant recipients who
developed active TB infection within 5 months post-transplant
vs. patients who developed active TB infection after 5 months
(36% vs. 17%, p = 0.04) [21–23].
Question 1.f
Is there a role for prophylaxis of fungal and viral infections
(excluding HBV) in liver transplantation candidates?
Statement 1.f
Based on current available data prophylaxis of both fungal and
viral infections is not recommended in liver transplant candi-
dates (III C).
Comment: IFIs and viral infections are important causes of
morbidity and mortality in solid organ transplant recipients
[10,24].
Question 1.g
Should surveillance of infections in liver transplant candidates be
performed while on the waiting list?
Statement 1.g
During waiting time a periodical surveillance for viral infec-
tious risk may be advisable. HIV 1–2 Ab, CMV Ab (IgG), HSV
1–2 Ab (IgG), VZV Ab (IgG), EBV Ab (EBNA-Ab, VCA IgG-IgM),
HHV 8 and Toxoplasma Ab (IgG) should be performed in
seronegative recipients every 6 months while on the waiting
list (III C).vol. 60 j 1075–1089
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Question 1.h
Which is the proper infectious management in patients while on
the waiting list?
Statement 1.h
– Any clinical sign of infectious disease in liver transplant
patients on the waiting list has to be investigated in order
to give the patient an appropriate treatment (III B)
– Any infectious event has to be notiﬁed to the liver transplant
centre and the patient might be temporary suspended from the
list until complete resolution, according to a multisciplinary
transplant team decision (III B)
– In case of MDR bacteria colonization/infection, eligibility for
liver transplantation should be reconsidered by the team, on
a case-by-case basis (III B)
Comment: SBP is mainly caused by Enterobacteriaceae. Empir-
ical therapy is based on 3rd generation cephalosporins. Cefotax-
ime 2 g tid for 5 days is as effective as higher dosages and
longer treatments but it is not superior to other cephalosporins.
Orally or intravenously administered quinolones have shown
the same efﬁcacy as cephalosporins, even though in studies char-
acterized by a low statistical power. SBP treatment with quino-
lones should be avoided if previous prophylaxis with
norﬂoxacin had been instituted. Aminoglycosides should be
avoided for risk of renal toxicity. Patients with bacterial infec-
tions other than SBP should be treated according to speciﬁc
guidelines for single infections (e.g., pneumonia, Skin and Soft
Tissue Infections (SSTI), Urinary Tract Infection (UTI) etc. and
local epidemiology of bacterial resistance) [25].
Post-transplantation
Question 2.a
Is there a correlation between type of infection and time after
liver transplantation?
Statement 2.a
Time after liver transplantation correlates with the type of infec-
tion (II A).
Comment: Three time intervals can be identiﬁed between liver
transplantation and types of infection.
(1) First month after surgery when opportunistic, donor-
derived and surgical infections are more prevalentTable 1. Features and work-up of most frequent post-transplant infections.
Infection Features Wor
Abdominal 
infections
Risks: duration of surgery and re-transplantation Bloo
Urin
Wound 
infections
S. aureus, streptococci, gram(-) anaerobes; 
fungi 
Gram
cultu
CR-BSI S. aureus, enterococci , gram(-) 
(Pseudomonas spp.); Candida spp.
Bloo
(CVC
UTI Gram(-) bacilli, enterococci Urin
LRTI Gram(-) bacilli, S. aureus Spu
BAL, bronchoalveolar lavage; CBC, complete blood count; CR-BSI, Catheter-related bloods
Endoscopic retrograde cholangio-pancreatography; UTI, urinary tract infection; LRTI, low
Journal of Hepatology 2014(2) Between 2–12 months post liver transplantation when
opportunistic and community acquired infections are
prevalent
(3) More than 12 months after surgery the rate of rare oppor-
tunistic infections (TB, Cryptococcus, Rhodococcus, Nocar-
dia, etc.) increases
Comment: Bacterial pathogens are the main causes of infection
post liver transplantation. It is important to identify the high-risk
populations [26,27].
Question 2.b
Which is the timing of infectious episodes and the appropriate
diagnostic work-up following liver transplantation?
Statement 2.b
– Diagnostic work-up in the early post liver transplantation
phase includes detection and management of donor-derived,
intra-abdominal and wound infections, UTIs, catheter-related
bloodstream infections (CR-BSIs) and LRTIs caused by hospi-
tal-acquired organisms (I A) (Table 1)
– Deﬁned post-LT time points can be identiﬁed (III A):
 Early post-LT infections (<1 month): Surgical complica-
tions and prolonged hospitalization/intensive care unit
(ICU) are risk factors for abdominal infections due to bac-
terial and Candida spp. (i.e., abscesses, cholangitis, or
peritonitis)
 Intermediate period: Opportunistic infections (from 2 to
12 months). Careful medical history (recent travels, con-
tacts with animals, vector exposure, etc.) has to be col-
lected if an opportunistic infection is suspected
 Late post-LT infections (>12 months): Community
acquired infections (ﬂu, LRTI, UTIs) often severe and com-
plicated; TB, Nocardia, Rhodococcus, Legionella, etc.
Comment: The diagnostic work-up and therapy (empirical or
targeted), should be performed by a multidisciplinary team,
including an expert in transplant infectious diseases.
Atypical presentations, poor outcomes and nosocomial anti-
microbial-resistant pathogens must be considered [28]. Empiric
anti-microbial therapy is usually indicated.
Question 2.c
Are there risk factors for post-LT infections?kup level I Workup level II
d tests (CBC, etc.)
e and blood cultures
CT scan or US
ERCP
Liver biopsy
 stain and purulent discharge 
res
US/CT if collection suspected
d cultures 
 and peripheral vein)
Echocardiography
e and blood cultures Kidney imaging
tum culture and chest X-ray CT scan, BAL, thoracentesis
tream infections; CT, computed tomography; CVC, central venous catheter; ERCP,
er respiratory tract infection; US, ultrasound.
vol. 60 j 1075–1089 1079
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Statement 2.c
Risk factors have been identiﬁed and serve as surveillance crite-
ria. They can be grouped as follows (II B):
– Patient factors
 Age
 MELD score >30; DMELD (recipient MELD  donor age)
>1600
 Malnutrition
 Prolonged hospital stay and catheters before OLT
 Acute liver failure
 Previous infections (SBP, sepsis, pneumonia, CMV, UTI)
 Previous TB
 >48 h ICU in-patient pre-LT
– Donor factors
 Prolonged ICU stay of donor
 Donor infections
 Marginal graft
– Surgical factors
 Choledochojejunostomy
 Prolonged surgery (>12 h)
 Re-operation, Re-transplantation
 >15 U transfusions
– Post-LT factors
 Mechanical ventilation
 Level and type of immunosuppression (i.e., use of monoclo-
nal and polyclonal antibodies)
 Primary non-function, hepatic artery thrombosis, portal
vein thrombosis, ischaemic cholangitis, biliary strictures
and ﬁstulae
 Post-transplant sclerosing cholangitis
Comment: Several risk factors correlate with the increasing
risk of infection. Peritonitis is more frequent in case of high
MELD, prolonged surgery, choledocho-jejunostomy, dialysis,
bleeding, hepatic artery thrombosis, and hepatic artery stenosis
[26,27,29–34].
Question 2.d
How to screen and monitor for donor-derived infections?
Statements 2.d
Aim of infectious disease screening in donors are (AIII):
– Identify infections which may exclude organ and tissue
donation
– Establish strategies for prevention of post-transplant infection
– Implement preventive measures (i.e., vaccination or
prophylaxis)
Organ donors are screened for infectious risks on the basis of
national organ-procurement standards (risk of false positive and
false negative) (BIII) [35,36].
Additional tests are generally recommended for donors travel-
ing, living or originating from endemic areas (BIII):1080 Journal of Hepatology 2014– HIV antibody
– HBsAg, HBsAb, HBcAb, HCV antibody
– Treponemal and non-Treponemal testing (usually TPHA or
TPPA, VDRL or RPR)
– Cytomegalovirus antibody (IgG only)
– EBV antibody
– HSV 1 and HSV 2 antibody (IgG only)
– VZV antibody (IgG only)
– Toxoplasma antibody (IgG only)
– Blood, sputum (BAL), and urine cultures
– Nucleic acid ampliﬁcation testing (NAAT) for HIV, HCV, HBV in
not established infectious risk donors (Supplementary
Table 3)
Question 2.e
Is microbiological surveillance useful?
Statement 2.e
Patients should be investigated with microbiological surveillance
after transplantation (II A).
Comment: Site-speciﬁc colonization study is useful for methi-
cillin resistant Staphylococcus aureus (MRSA), Vancomycin resis-
tant enterococci (VRE), extended-spectrum beta-lactamase
(ESBL), and carbapenemase-producing GNB. Other surveillance
should be adopted according to the donor and recipient pretrans-
plant data. Microbiological surveillance on biliary ﬂuids is not
mandatory [29,31,37].
Question 2.f
What are the most relevant criteria for bacterial prophylaxis?
Statement 2.f
– Criteria for prophylaxis have been identiﬁed to obtain MRSA
decolonization and to prevent VRE and MDR Gram (-) infec-
tions (II A): MRSA decolonization is achieved with 2% intrana-
sal mupirocin and chlorexidine baths. VRE and MDR GNB can
be prevented by contact isolation
Comment: There is no evidence of the use of SDD (norﬂoxacine
and a paste of polimixine-tobramicine amphotericin-AmB).
Vancomycin is not utilized due to the increasing risk of VRE selec-
tion [27,31].
Question 2.g
Which are the drugs of choice for bacterial prophylaxis?
Statement 2.g
– Surgical prophylaxis in low risk patients should be performed
by cefotaxime and ampicillin or by piperacillin-tazobactam
(based on local epidemiology) not exceeding 48 h (II A)
– Cotrimoxazole (TMP-SMX) is the drug of choice for its activity
against Pneumocystis jiroveci, Nocardia spp., Toxoplasma gondii
and Listeria spp. (II A)
Comment: Indication for surgical prophylaxis must be deﬁned
according to the local epidemiology [38]. The measurement of
efﬁcacy of prophylactic regimens in reducing the rate of post-LT
infections is difﬁcult, because no controlled studies havevol. 60 j 1075–1089
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compared prophylaxis with no prophylaxis or the efﬁcacy of anti-
microbial prophylactic regimens different from cefotaxime and
ampicillin. Indeed, a wide variety of antimicrobial combination
regimens are utilized among different centres [38]. Traditional
prophylactic regimens in liver transplantation have consisted of
a third-generation cephalosporin (usually cefotaxime, because
of its antistaphylococcal activity) plus ampicillin to cover entero-
cocci. A reasonable alternative is Piperacillin-tazobactam which
covers enterobacteriaceae, enterococci and Pseudomonas.
Question 2.h
How should Surgical Infections be managed in the early post-LT?
Statement 2.h
– SSI is a multifactorial event linked to local epidemiology, risk
factors and antimicrobial prophylaxis (I)
– Once intra-abdominal infection is suspected the diagnosis is
based on radiographic imaging (CT scan or ultrasound) and
in the presence of ascites both neutrophil count and culture
of ascitic ﬂuid in blood-culture vials is required (I A)
– Treatment of SSI is based on combination of surgical debride-
ment and empiric antimicrobial therapy according to local
epidemiology and Gram stain results. Targeted therapy should
be based on ﬂuid culture (II A)
Comment: Surgical infections (wound infections, peritonitis,
abdominal and hepatic abscesses) can lead to intra-abdominal
infections and account for 27–47% of bacterial infections in liver
transplant recipient. A prevalence up to 10% has been described
in liver transplant recipient: retransplantation, duration of sur-
gery, choledocho-jejunostomy have been identiﬁed as risk fac-
tors. Gram (-) bacilli and Enterococcus species are frequent.
MDR pathogens are frequently found in abscesses [22–
24,26,27,39].
Question 2.i
What is the diagnostic management of post-LT CMV infection?
Statement 2.i
The standard for CMV-infection surveillance is weekly or twice a
week CMV monitoring (real-time PCR) after the ﬁrst positive
result, for the ﬁrst three months after transplantation (I A).
– Three months is an adequate period for CMV-reactivation
monitoring (I A)
– Serology has no role in post-LT CMV disease diagnosis (II)
– Cultures (blood and urine) are of limited utility for CMV dis-
ease management (II)
– CMV pp65 antigenemia (semi-quantitative test) and CMV
viral load (NAT) are acceptable options for diagnosis, pre-
emptive therapy and monitoring response to therapy (II A)
Comment: 30–60% of solid organ transplant (SOT) recipients
are newly infected or reactivate latent CMV infection after
transplantation.
In pre-emptive setting of targeted groups of patients, labora-
tory monitoring of CMV infection is performed by pp65 antige-
nemia or NAT at regular weekly or twice a week intervals. Lack
of standardization across different laboratories is a problem forJournal of Hepatology 2014both tests and centres need to validate their own threshold val-
ues. A safe cut-off determined by real-time PCR was demon-
strated to range between 100,000 and 300,000 copies/ml of
whole blood according to the type of commercial test used.
The suggested cut-offs for pre-emptive therapy have been
recently validated and are homogeneously and reliably quanti-
ﬁed by different methods (both commercial and in-house) and
by different laboratories. It is however recommended that each
transplant center should work with their clinical laboratories to
deﬁne the relevant viral load thresholds for their clinical appli-
cations. In 2011, the WHO released the ﬁrst International Refer-
ence Standard for the quantiﬁcation of CMV nucleic acid, and
laboratory and commercially developed CMV QNAT assays
should now be calibrated to this standard. This may ensure uni-
formity in viral load reporting, thereby facilitating to deﬁne viral
thresholds for various clinical applications. In case of persis-
tently positive CMV-DNA antiviral resistance can be screened
in vitro and treatment switch to foscarnet in case of docu-
mented resistance is advisable [40–47].
Deﬁnitions for CMV in the transplant setting• CMV infection: evidence of CMV replication regardless 
of symptoms
• CMV disease: CMV infection + symptoms (i.e., viral 
syndrome with fever, malaise, leuko/thromboctopenia, 
tissue-invasive disease)
• Late CMV disease: according to the length of prophylaxis 
(3 or 6 months) CMV disease with attributable symptoms, 
occurring 3 to 6 months post-SOT. May be primary 
infection (D+/R-) or reactivation/superinfection (R+). May 
present with atypical symptoms
- Diagnosis can be missed
- Patient may not be followed by primary centre or may 
not be followed as closely
• Primary infection: in case of the combination Donor(+)/
Recipient(-), over 90% of the recipients develop CMV 
infection
• In case of reactivation of endogenous latent infection, 
around ~15% of recipients become ill 
• Superinfection: in case of combination Donor(+)/
Recipient(+) but with D(+) reactivation, around ~25% of 
the recipients become illQuestion 2.l
What is the treatment management of post-LT CMV infections/
disease (reactivation, primary infection, reinfection)?Statement 2.l
– Prevention strategies based on concomitant determination of
CMV-DNA and speciﬁc T cell responses in the post-transplant
period might be useful (II B)vol. 60 j 1075–1089 1081
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– ‘‘Universal prophylaxis’’: D+/R, (3–6 months post-TX): val-
ganciclovir 900 mg/day, oral ganciclovir (3 g/day), or intrave-
nous ganciclovir (5 mg (kg/day)
– ‘‘Pre-emptive therapy’’: the most widely adopted starting cri-
teria for pre-emptive CMV antiviral therapy are [48,49]:
 In CMV seronegative and/or seropositive: DNAemia
P100,000 copies/ml
 In case of Steroid boluses or ATG/OKT3 therapy for Rejec-
tion: any value of DNAemia
– The drug of choice for treatment is ganciclovir (5 mg/kg bid
i.v.). Valganciclovir (900 mg bid oral) is an alternative,
although it is not approved for this indication in CMV seropos-
itive recipients [48–50] (II A)
– Pre-emptive treatment should be stopped after two consecu-
tive negative CMV viral load performed during treatment) (II
A)
Comment: The optimal duration of intravenous or oral treat-
ment after resolution of clinical signs is uncertain. Serial PCR of
CMV DNA offers an objective measure of the degree of viraemia
and may help to guide the duration of treatment. In all recipients
antiviral therapy must be continued until DNAemia clearance.
Recurrent episodes of active infection are usually treated with
additional courses of ganciclovir starting with DNAemia values
P100,000 copies/ml.
Question 2.m
How to diagnose invasive fungal infection (IFI)?
Statement 2.m
– According to the 2008 European Organization for Research
and Treatment of Cancer/Invasive Fungal Infections Coopera-
tive Group (EORTC) deﬁnitions, there are 3 levels for the diag-
nosis of IFI: ‘‘proven,’’ ‘‘probable,’’ and ‘‘possible.’’ These
criteria may be applied to SOT recipients with the aim of har-
monizing clinical and epidemiological research (II A):
 At least one positive blood culture for Candida spp. or
other pathogenic fungi
 A positive culture for a pathogenic fungus from a speci-
men collected from a normally sterile site
 A positive culture for a pathogenic fungus from a biopsy
specimen (taken across a potentially colonized mucosal
surface) plus histopathology conﬁrming fungal elements
in tissue with local inﬂammation
 Evidence of fungal endophthalmitis based on dilated fun-
doscopic examination
 Positive histopathology for fungal elements in a deep tis-
sue biopsy
 A positive culture for a mould (e.g., Aspergillus spp., Fusar-
ium spp., Zygomycete) from a non-sterile body site
together with clinical, histopathologic or radiologic evi-
dence consistent with IFI
 Positive cryptococcal or histoplasma antigen test and
clinical or radiographic evidence consistent with Crypto-
coccosis or Histoplasmosis
 A positive culture or histopathologic evidence of an ende-
mic mycosis (e.g., Blastomycosis, Histoplasmosis or
Coccidioidomycosis)1082 Journal of Hepatology 2014– Invasive diagnostic procedures are required for an accurate,
timely diagnosis (II B)
– Diagnostic procedures may be performed by means of imag-
ing techniques and bronco-alveolar lavage (BAL) (II A)
– A proven diagnosis of IFI depends on recovery with micro-
scopic evidence or isolation from cultures of fungal elements
from a sterile body site or in diseased tissue (III A)
Comment: Range of IFI incidence after liver transplantation is
reported to be wide (4–42%). According to the most recent data
based on strict deﬁnitions, the incidence is usually reported to
be lower (<10% range 2–8%). Among IFI, the majority are sus-
tained by Candida species (from 68 to 78.7%) followed by Asper-
gillus species (7.9–11%) and Cryptococcus neoformans (6–7.1%)
Timing of IFI ranges from early (<3 months) to late (>6 months)
period after liver transplantation [27,51–56].
Question 2.n
What are the indications for perioperative prophylaxis for inva-
sive fungal infections (IFI) in post-LTR?
Statement 2.n
– Risk factors for Candida and Aspergillus infections have been
identiﬁed (II B) (Table 2)
– According to the number of factors present in the post-LT per-
iod, low and high-risk patients are recognised (II B)
– Risk factors are relevant to drive targeted prophylaxis/early or
empirical treatment (II B)
Comment: Targeted antifungal prophylaxis (the use of an anti-
fungal agent in a subgroup of transplanted recipients at higher
risk for the presence of predisposing conditions and/or risk fac-
tors for Candida and for Candida and Aspergillus) represents the
ideal treatment strategy. Different therapeutic strategies are to
be considered for the risk of Candida and Aspergillus
[10,27,51,57–63]. Antifungal prophylaxis is suggested only for
high-risk patients (ﬂuconazole 400 mg/kg daily or liposomal
AmB (L-AmB) 3–5 mg/kg daily up to 4 weeks. or until resolution
of symptoms). All of the azole-derivative antifungal agents
decrease the metabolism of calcineurin inhibitors and Sirolimus
resulting in modest to profound increases in serum concentration
and AUC. The interaction of ﬂuconazole with calcineurin inhibi-
tors is both dose- and drug-dependent. At modest doses (100–
200 mg/day) of ﬂuconazole used for nonsystemic candidiasis,
effects on CsA are minor, while moderate to signiﬁcant increases
are seen with Tacrolimus. At doses of ﬂuconazole required for
systemic fungal infection (e.g., 400 mg for cryptococcosis or can-
didemia), dose reduction of immunosuppressants is required. The
new echinocandin antifungal agents provide alternatives to the
use of azole derivatives [62,63,61].
Question 2.o
What is the management of invasive fungal infections in liver
transplant recipient?
Statement 2.o
– In invasive candidiasis (IC) ﬂuconazole or an echinocandin are
recommended as initial therapy (II B)
– In invasive aspergillosis voriconazole is the drug of choice (I A)vol. 60 j 1075–1089
Table 2. Risk factors for post-transplantation fungal infections.
Risk factors for Candida Risk factors for Aspergillus
Renal replacement therapy
Surgical factors
• Prolonged operation time (>11 hr)
• Second surgical intervention within 5 days
• Choledochojejunostomy anastomosis
• >40 units of blood products during surgery
Dialysis
Surgical factors
• Retransplantation
Microbial factors
• Early fungal colonization (within 3 days)
• Documented colonization (nasal, pharyngeal or rectal)
Microbial factors
• CMV infection
• Prior colonization 
Acute liver failure Acute liver failure
CMV, cytomegalovirus.
JOURNAL OF HEPATOLOGY– Limitations in liver transplant recipient are interference with
immune-suppressants and liver toxicity. L-AmB is considered
an alternative therapy (III B) (Table 3)
Question 2.p
What is the management of MDR Infections in liver transplant
recipients?
Statement 2.p
– Careful screening and antibiotic selection for multidrug resis-
tant pathogens (MDR) pre- and post-transplant is mandatory
and the identiﬁcation of MDR requires experienced microbiol-
ogy laboratories (III A)
– An expert opinion in antimicrobial treatment of multidrug
resistant organism is mandatory for the choice of the right
drug regimen (III A)
– In case of Vancomycin resistant enterococci (VRE) (III A):
 Transthoracic echocardiography (TTE), Transesophageal
echocardiography (TEE) and biliary tract infections workup
are indicated when multiple positive blood cultures are
identiﬁed
 Wounds debridement, abscesses drainage, and foreign
bodies removal are recommended
 Limit broad spectrum antimicrobials use is indicated
– Methicillin resistant S. aureus (MRSA) (III A)
 Monitoring of MRSA colonization must be adopted
 Isolation and decontamination is suggested
– Multi drug resistant (MDR) Gram (-) extended spectrum
beta-lactamase (ESBL) (III A)
 The identiﬁcation requires experienced microbiology
laboratories
 Limited options for therapy – adjust according to individ-
ual susceptibility testing
Comment: MRSA, VRE, ESBL and carbapenem-resistant gram-
negative bacilli (KPC, NDM-1) are increasing worldwide
[31,39,64–87] (Table 4).
Question 2.q
What is the diagnostic work-up in liver transplant recipients with
lower-tract respiratory infections?Journal of Hepatology 2014Statement 2.q
– Nasopharyngeal swab for respiratory viruses PCR or antigens,
viral PCRs on blood, fungal and acid-fast bacilli (AFB) blood
cultures, sputum culture and chest X-ray must be performed
(I A)
– More sensitive diagnostic tools, i.e., thoracic CT scan, BAL, and
thoracentesis in case of pleural effusion should always be con-
sidered (III A)
Comment: Leukocytosis, new inﬁltrate on chest ﬁlm, and hyp-
oxemia is reported as the typical triad in post-LT lung infections
[88]. Various causes, including opportunistic (P. jiroveci, atypical
mycobacteria, viruses), rare pathogens (i.e., metapneumovirus,
Rhodococcus equi, etc.), and highly resistant germs (MRSA, Pseu-
domonas, Stenotrophomonas, Bulkholderia, carbapenem-resistant
Gram (-)) should be considered. Fever, increased sputum, dysp-
noea and/or low oxygen saturation are common [88]. Pneumocys-
tis jiroveci pneumonia (PJP) prophylaxis, according to the
international guidelines, is recommended for 6–12 months
post-transplant (Tables 5 and 6).
Question 2.r
What is the management of tuberculosis in liver transplant
recipients?
Statement 2.r
– In latent TB: Obtain TST (BII), medical history and chest X-ray (II A)
 IGRAs not optimal in high immunosuppression and cirrho-
sis (II D)
 Exclude active TB (III B)
 Treatment: isoniazid 300 mg/day + Vitamin B6 for 6–
9 months (I B) waiting for stable liver function (III B)
 Rifampicin (RMP) + pyrazinamide (PZN) not recommended
due to toxicity (II C). If isoniazid (INH) intolerance, strict f/u
and rifampicin 600/day p.o. for 4 months (III B)
– In active TB:
 Efforts to obtain an isolated organism for sensitivity testing
should be made (III A)
 Avoid rifampicin due to difﬁculty in maintaining adequate
levels of immunosuppression and risk of organ rejection (III
B)
 Prolonged treatment (12–18 months) recommended in rif-
ampicin-sparing regimens and extrapulmonary TB (III B)vol. 60 j 1075–1089 1083
Table 3. Treatment of fungal infections in liver transplant recipients.
Candidiasis and aspergillosis
Site of infection
Invasive candidiasis Invasive aspergillosis
Empirical treatment if IC suspected*. 
• Echinocandin preferred in haemodinamically unstable or 
previous azole exposure (BIII);
• L-AmB is an alternative (III C)
Empirical treatment only if high risk factors + microbiological/clinical 
criteria. L-AmB preferred if toxicity risks, azole exposure (III C)
Targeted treatment
• Fluconazole 800 mg (loading: 12 mg/kg) then 400 mg daily 
(BII) or an echinocandin
• Caspofungin (loading 70 mg, then 50 mg day) or 
micafungin (100 mg day) or anidulafungin (loading 200 mg, 
then 100 mg day) (AII
II A)
Targeted treatment
• Voriconazole (loading 6 mg/kg bid then 4 mg/kg bid) (I A); OS if 
ClCr <50 ml/min (III B) or
• L-AmB (3-5 mg/kd day) (I A)
• Caspofungin (BII) and posaconazole as alternative/salvage (III C)
Cryptococcosis
Site of infection
Meningoencephalitis/disseminated disease Pulmonary
Induction (2 weeks) 
• I B)
or
• L-AMB 3-4 mg/(kg day) (II B) 
or 
• AmB lipid complex 5 mg/(kg day) (III C)
Fluconazole 400 mg/day for 6-12 months (II C)
Disseminated disease must be excluded in all patients (III A)
Asymptomatic forms require treatment in SOT (III B)
meningoencephalitis
Consolidation (8 weeks)
• Fluconazole 400-800 mg/day (II B)
Maintenance (6-12 months)**
• Fluconazole 200 mg/day (II B)
) ± stepdown to fluconazole after 3-5
days if susceptibility confirmed (
*Diffuse pulmonary infiltrates and acute respiratory failure treated as
L-AmB 3-4 mg/(kg day) plus flucytosine 100 mg/(kg day) (
⁄Useful monitoring of cryptococcal antigen titres.
⁄⁄(1) Persistent fever (38 C) despite broad spectrum therapy for 96 h and (2) no other known cause of fever plus (3) Candida colonization for the same species from at least
2 non-contiguous (including non-sterile) sites and/or (4) the presence of speciﬁc risk factors and/or, (5) clinical-radiological suspicion of IC and/or detection of –D glucan in
serum.
AmB, amphotericin B; IC, invasive candidiasis; L-AMB, liposomal-amphotericin B; SOT, solid organ transplantation; TDM, targeted-drug monitoring.
Frontiers in Liver Transplantation Alternative regimens: isoniazid + ethambutol + pyrazina-
mide or use of quinolones (moxiﬂoxacin, levoﬂoxacin) (II C)
 In HIV-infected liver transplant recipient avoidance of rifa-
mycins + addition of a quinolone are recommended (III B)
 Consultation with a TB specialist is mandatory [89,90] (III
A)Comment: Latent tuberculosis is not a contraindication to liver
transplantation but requires pre or post-transplant treatment
according to the clinical conditions and the international
guidelines.
Both latent (anergy – skin test negativity) and active TB are
difﬁcult to diagnose. There is no wide literature-based consensus
on TB infection management, and most clinical practice is based
upon experts’ opinion [91–93]. It is recommended that the
approach to the treatment of TB in solid organ transplant recipi-
ents is similar to immunocompetent hosts. However, the follow-
ing important issues speciﬁc to solid organ transplant recipients
should be highlighted: (a) rifamycin-containing regimen is
strongly preferred for both severe and localized non-severe TB
due to the potent sterilizing activity of such regimens and the
importance of preventing the emergence of resistance; (b) the1084 Journal of Hepatology 2014rifamycins (especially rifampicin) reduce serum concentrations
of tacrolimus, cyclosporine, rapamycin (sirolimus), and everoli-
mus via induction of the cytochrome p450 isoenzyme CYP3A4,
and this bears the risk of inducing rejection. Therefore, dose of
the CNI or rapamycin should be increased accordingly and serum
concentrations regularly monitored.Question 2.s
What is the management of the most common food-borne dis-
eases in liver transplant recipients?Statement 2.s
– Most foodborne diseases are self-limited and require only
supportive care while in immunocompromised patients an
antibiotics treatment is often required (III B) (Table 7)
– Prevention is essential in reducing the cases of foodborne ill-
ness. Education of patients and their caregivers is crucial (I B)
Comment: Salmonellosis, listeriosis, and parasitic diseases
may cause severe infections in liver transplant recipients [94–
96].vol. 60 j 1075–1089
Table 4. Management of drug resistant pathogens.
Multidrug resistant Gram(-) (MDR)
Treatment Notes
Carbapenems (II A) Not to be used against  carbapenemase-producing bacteria
IV Colistin (II B) Lack of data, associations/aerosol, renal toxicity
Tygecycline (II C) Not to be used in UTI, bacteremia or high-density infections
Vancomycin-resistant Enterococci (VRE)
Treatment options Pros Cons
Linezolid (III B) Oral formulation, reaches high bile concentrations 
in bile 
Possible resistance, long term toxicity, bactero-
static
Daptomycin (III B) Once daily administration, synergism with RMP 
and other antimicrobials
Lack of data
Quinopristin/dalfopristin (II C) Active on E. faecium Not to be used against E. faecalis, requires CVC 
placement
Tygecycline (II C) Reaches high concentrations in bile Bactero-static, not to be used in ICU/bacteraemia/
lung infections
Methicillin-resistant Staphylococcus aureus (MRSA)
Treatment Notes
Vancomycin (I B) Not to be used if MIC ≥2 μg/ml, monitoring of levels warranted
Daptomycin (II B) Not to be used in pneumonia cases
Linezolid (II B) Bactero-static (reduced effect in bacteremia/infective endocarditis)
Telavancin (III C) Not to be used in kidney failure, limited data available
CMV, cytomegalovirus; CVC, central venous catheter; D+, donor positive; ESKD, end-stage kidney disease; ICU, intensive care unit; LTR, liver transplant recipient; LTX, liver
transplantation; MIC, minimal inhibitory concentration; RMP, rifampicin; TX, transplantation.
Table 5. Likely respiratory pathogens in solid organ transplant recipients based upon the presenting chest X-ray radiographic pattern.
Diffuse interstitial-alveolar Lobar-segmental Reticulonodular Discrete nodule
• CMV
• 
• RSV
• Adenovirus
• P. jiroveci
• Bacterial
• Legionella
• Rhodococcus equi
• Cryptococcus
• 
• Nocardia
• M. tuberculosis
• Non-tuberculous 
mycobacteria 
• P. jiroveci
• Histoplasmosis
• Cryptococcus
• Aspergillus
• Other mycelia
• M. tuberculosis
• Nocardia
• PTLD (EBV)
• Cryptococcus 
• Histoplasmosis
RSV Influenzae
Influenza
EBV, Epstein-Barr virus; CMV, cytomegalovirus; M tuberculosis, Mycobacterium tuberculosis; P jiroveci, Pneumocystis jiroveci; PTLD, post-transplant lymphoproliferative
disease; RSV, respiratory syncytial virus.
JOURNAL OF HEPATOLOGYQuestion 2.t
What is the management of EBV, and HHV8 infections in liver
transplant recipients?
Statement 2.t
– Epstein Barr virus (EBV) infection Monitoring regularly EBV-DNA in the same laboratory in
D+/R (III A)
 Monitoring of EBV-speciﬁc CTL activity is also helpful (II B)
 Diagnosis is made by tissue examination (II A)
 EBV-DNA (PCR) and EBV-speciﬁc CTL activity correlate
with risk (II A) but inter-laboratory variability must be
taken into account (III A)
– HHV-8 Infection
 HHV-8 viral load monitoring useful in D+/R in endemic
areas (II A)
 Diagnosis and KS monitoring preferred by NAT (II A)Journal of Hepatology 2014 In recipients with positive HHV8 serology or receiving an
organ from a positive HHV8 serology donor the monitoring
of HHV8-DNA post-transplant is strongly recommended (III
B) (Supplementary Table 5)
 Management of KS:
 Minimization of immunosuppression and switch to an
mTOR inhibitor (either sirolimus or everolimus) (II A)
 Lesions removal is required (II A) [97–100]
Comment:
Epstein Barr virus (EBV) infection: EBV is responsible for the
majority of PTLD. Recognized risk factors are: young age, D+/R,
CMV positivity, T cell depleting therapies.
HHV-8 Infection: Kaposi sarcoma (KS) and other proliferative
diseases are frequently associated. This condition presents
geographic variability (5–20% prevalence in Mediterranean area)
[97,101].vol. 60 j 1075–1089 1085
Table 6. Pneumocystis jiroveci pneumonia: Prophylaxis and therapy.
Prophylaxis
Primary Alternative Comments
• TMP-SMX, SS or DS once/day
or
• DS three times/week
• Dapsone, 50-100 mg/day
or
• Pentamidine aerosol, 300 mg 
inhaled monthly via Respirgard 
II® nebulizer
or
• Atovaquone, 1500 mg/day
• Duration: 6-12 months post-transplant. 
Consider prophylaxis during and after 
treatment of acute rejection (duration 6 wk)
•  of TMP-SMX: most 
Toxoplasma and Nocardia infections can be 
prevented (as are some GI infections, UTI, and 
RTI
• Dapsone
population
Therapy
Hospitalized patient, PaO2 <70 mmHg (<10 kPa)
Primary Alternative Comments
TMP-SMX 15 mg/kg/day of TMP component 
IV divided in three doses + prednisone (if 
PaO2 <70 mmHg) for 21 days
Primaquine 15-30 mg PO q24h + 
clindamycin 600 mg IV q8h x 21 days 
or
Pentamidine 4 mg/kg/day x 21 days + 
prednisone (see comments)
Based on data from HIV patients: consider 
concomitant use of corticosteroids if PaO2 <70 
mmHg: prednisone (start before TMP-SMX) 40 mg 
PO BID for 5 days, then 40 mg PO q24h for 5 days, 
then 20 mg PO q24h for 11 days)
Secondary prophylaxis recommended
Additional benefit
: check G6PD deficiency in risk
Less evidence of efficacy with alternative therapy
BID, bis in die; DS, double strength; GI, gastrointestinal; HIV, Human immunodeﬁciency virus; IV, intravenous; PaO2, partial pressure of arterial oxygen; PO, per os; RTI,
reproductive tract infection; SS, single strength; TMP-SMX, trimethoprim sulfamethoxazole.
Table 7. Blood-borne infections after liver transplantation.
Pathogen Features Risk factors Management
Salmonella spp • High risk of bacteremia (2-14%) • Antirejection treatment
• Recurrent (latent) infections
• Fluoroquinolones or III 
generation cephalosporin
• Surgery (vascular prosthesis 
infection) (II B)
Listeria spp • Within 2 months from LT (TMP/
SMX prophylaxis may reduce 
the risk)
• Acute rejection, CMV disease, 
DM
• Ampicillin ± gentamycin or 
TMP-SMX
• Surgery if brain abscess (II B)
Parasites
Cryptosporidium spp 
• Low response rates to 
treatment.
• Prophylaxis with TMP/SMZ for 
6 months recommended
• Contaminated water
• D+/R-
• Undercooked meat
• Azithromycin, paromomycin 
(II C)
• pyrimethamine/sulfadiazine 
(I B)
CMV, cytomegalovirus; D+/R, donor positive/recipient negative; DM, diabetes mellitus; LT, liver transplantation; TMP-SMX, trimethoprim sulfamethoxazole.
Frontiers in Liver TransplantationQuestion 2.u
What is the management of CNS infections in liver transplant
recipients?
Statement 2.u
– Speciﬁc diagnostic tools for CNS infection in liver transplanta-
tion have been identiﬁed (I A) (Supplementary Table 6)
– Prompt administration of therapy on suspicion of the diagno-
sis without deﬁnitive proof is needed to control infection (III
A)
Comment: the following time points for CNS infections can be
identiﬁed in the post–LT period (Supplementary Tables 7 and 8):
– Early post-LT: 40% of CNS infections in liver transplant recipi-
ent (donor-derived, complication of surgery or ICU)
– 1–6 months Post liver transplantation: Aspergillus, Listeria,
Nocardia, Candida dissemination, HHV61086 Journal of Hepatology 2014– Late post-LT: subacute-chronic meningitis (rare) due to Cryp-
tococcus, Coccidioidomycosis, Histoplasmosis, progressive multi-
focal leukoencephalopathy (PML, due to JC virus), EBV
associated B-cell lymphoproliferative disease
Question 2.v
What is the treatment management of Nocardiosis in liver trans-
plant recipients?
Statement 2.v
– Speciﬁc organ-related therapeutic regimens for Nocardiosis in
liver transplantation recipients have been identiﬁed (II B /III B)
(Table 8).
Comment: Rates of Nocardiosis in liver transplant recipient
varies between 0.7% and 3.5%. Nocardiosis is unlikely earlier than
1 month post-liver transplantation (can exceptionally be seen invol. 60 j 1075–1089
Table 8. Organ-related therapeutic regimens for nocardiosis in LT recipients.
Regimens
Pulmonary; stable
TMP-SMX 15 mg/(kg day in 3-4 divided doses) (II B) for 6-12 months
Critical, disseminated, CNS
Imipenem (500 mg q 6) + TMP-SMX (BII) or amikacin (10-15 mg/kg day) (III C) for 9-12 months (III B)
Alternative
Meropenem 1-2 g q8h (III B)
Linezolid 600 mg q12h (III C)
Recommendations
• Antimicrobial association preferred in the seriously ill (III C)
• Susceptibility tests recommended for alternative regimens (III B) 
• IV >3 wk  in the seriously ill (III B)
• Drainage of brain abscesses and MRI follow-up for relapses (III B)
CNS, central nervous system; IV, intravenous; MRI, magnetic resonance imaging; TMPSMX, trimethoprim sulfamethoxazole.
JOURNAL OF HEPATOLOGYcases of extremely high immunosuppression). The infection typ-
ically occurs via respiratory entry (i.e., inhalation of contami-
nated dust) with blood dissemination in 18–40% of cases with
granulomatous pulmonary forms and frequently multiple
abscesses (cerebral abscesses). The identiﬁed risk factors are:
high dose steroids, CMV disease, and severe hypogammaglobu-
linemia. Antimicrobial susceptibility varies with species. Delayed
onset of Nocardiosis can be observed because of TMP/SMZ pro-
phylaxis. Cephalosporins and minocycline can be used after ini-
tial therapy, however with variable outcomes [102].Conﬂict of interest
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